In the modern clinical landscape, patients suffering from rare, undiagnosed conditions often embark on a grueling "diagnostic odyssey"—a years-long journey of specialist referrals, inconclusive tests, and mounting medical bills. For many families, this period of uncertainty is the most traumatic aspect of their healthcare experience. A new study, published in Human Genetics and Genomics Advances, suggests that the key to shortening this journey lies in the timing of genetic intervention.
In an exclusive interview with HGG Advances, Dr. Tamara Roman, a Variant Analyst at UNC Health, discusses the findings of the NCGENES 2 project. Her paper, "Exome sequencing early in outpatient evaluation in NCGENES 2: Changing the course of the diagnostic odyssey?", provides a compelling argument for integrating exome sequencing (ES) into the initial stages of the outpatient evaluation process, rather than treating it as a "test of last resort."
The Core Challenge: Why Early Sequencing Matters
The fundamental premise of the NCGENES 2 study is that the current clinical pipeline for patients with suspected genetic disorders is inefficient. Traditionally, clinicians exhaust conventional diagnostic methods—such as metabolic panels, imaging, and single-gene testing—before authorizing comprehensive exome sequencing. By the time this technology is employed, patients have often spent months, if not years, navigating the healthcare system.
Dr. Roman’s research focuses on the impact of shifting this paradigm. By utilizing exome sequencing early in the outpatient evaluation, clinicians can potentially pinpoint pathogenic or likely pathogenic variants far sooner, allowing for tailored treatment plans and a significant reduction in the psychological and financial toll of the diagnostic search.
"I started this project as a postdoc," Dr. Roman explains, "and my interests include variant classification and investigating the clinical utility and impact of exome sequencing." Her work represents a bridge between high-level genomic research and the practical, daily realities of clinical geneticists and their patients.
Chronology of the NCGENES 2 Study
The NCGENES 2 study was not an isolated experiment but a large-scale, multidisciplinary effort that spanned several years. The project’s timeline was defined by three distinct phases:
Phase I: Planning and Integration
The research team recognized that implementing ES early in the clinical workflow required more than just technological capability; it required institutional buy-in. The team established a framework that integrated genetic counselors, laboratory geneticists, and research faculty from the outset. This phase ensured that when patients entered the clinic, the diagnostic infrastructure was ready to process, interpret, and communicate results efficiently.
Phase II: Clinical Implementation
During the implementation phase, patients presenting with clinical indications suggestive of a genetic etiology were offered early exome sequencing. Unlike standard practice, where ES might be the final step after years of searching, these patients received the test within the initial window of their outpatient evaluation.
Phase III: Evaluation and Reclassification
The final phase, which continues to inform the research today, involves the ongoing analysis of data. A critical component of the study was not just the initial diagnosis, but the long-term monitoring of Variants of Uncertain Significance (VUS). As medical databases grow and our understanding of the human genome improves, researchers like Dr. Roman must revisit previously interpreted data to determine if a VUS can now be confidently reclassified as pathogenic or benign.
Supporting Data and the VUS Conundrum
The success of any diagnostic protocol hinges on the accuracy of its results. However, the use of exome sequencing introduces a significant hurdle: the Variant of Uncertain Significance.
Dr. Roman emphasizes that while ES is remarkably effective at identifying causative variants, it also uncovers a high volume of genomic "noise." When a VUS is detected, clinicians face a difficult path. "These VUS can be challenging to interpret in the context of limited data," Dr. Roman notes. "This highlights the importance of periodically evaluating emerging data to potentially reclassify variants."
The NCGENES 2 study utilized a robust feedback loop. By keeping a registry of variants identified in the study, the team was able to perform longitudinal data assessments. Their findings underscore a critical takeaway for the genetics community: a genetic report should not be viewed as a static document, but as a living record that requires periodic updating as global genomic knowledge expands.
Multidisciplinary Collaboration: A Clinical Mandate
One of the most notable aspects of the NCGENES 2 project is its collaborative nature. Dr. Roman points to this as the most exciting aspect of the work. The study required a high level of synergy between disparate roles within the healthcare system.
- Clinical Geneticists: Provided the necessary phenotypic context, ensuring that the bioinformatics team knew exactly what to look for based on the patient’s symptoms.
- Laboratory Geneticists: Managed the high-throughput sequencing pipelines and initial data filtration.
- Genetic Counselors: Played a vital role in patient communication, helping families navigate the implications of genetic results—a task that is often as complex as the genomic analysis itself.
- Research Faculty and Students: Provided the analytical horsepower required to parse large datasets and refine interpretation protocols.
"I really enjoyed both the research and the clinical component," says Dr. Roman. "It was a very collaborative research project to assess exome sequencing in a clinical setting."
Implications for the Future of Genomic Medicine
The implications of the NCGENES 2 project extend far beyond the walls of the clinic. If early exome sequencing is adopted as a standard-of-care, the healthcare system could see a dramatic shift in how rare diseases are managed.
1. Reduction in Healthcare Costs
By eliminating the need for redundant, ineffective diagnostic tests, early sequencing may ultimately reduce the financial burden on healthcare systems and insurance providers, despite the higher upfront cost of genetic testing.
2. Improved Patient Outcomes
A faster diagnosis means faster access to targeted therapies, or in cases where no cure exists, the ability to stop searching and begin palliative or supportive care. This reduces the "diagnostic odyssey" and provides families with much-needed closure.
3. The Need for Continuous Education
Dr. Roman acknowledges the difficulties inherent in the field. "The field of genetics is rapidly evolving, and it can be challenging to stay updated and familiar with novel technologies and increased data." For young scientists and clinicians alike, the challenge is keeping pace with the exponential growth of genomic knowledge. The NCGENES 2 project serves as a model for how institutions can support this continuous learning through interdisciplinary cooperation.
Beyond Human Genomics: Inspiration from Nature
When asked about the most fascinating development in the field outside of her own work, Dr. Roman points to the intersection of synthetic biology and disease prevention. She cites the work of Dr. Kevin Esvelt and his team on heritable immunization in mice.
"In a recently published study, Kevin Esvelt, PhD, and his group used genetic engineering in mice to express a monoclonal antibody against Lyme-disease-causing bacteria, which was inherited across generations," she explains. This research into "heritable immunity" showcases the creative potential of modern genetic engineering. While the study is focused on ecological and public health outcomes, it highlights the innovative spirit that drives modern geneticists to think beyond conventional therapeutics.
Conclusion: A New Standard of Care?
The research conducted by Dr. Tamara Roman and her colleagues on the NCGENES 2 project provides a compelling roadmap for the future of diagnostics. By prioritizing early exome sequencing and fostering a culture of continuous variant re-evaluation, the medical community can do more than just diagnose; it can restore time and certainty to patients who have been left in the dark for too long.
As the technology becomes more accessible and the interpretation of genomic data becomes more refined, the "diagnostic odyssey" may soon become a relic of the past. For researchers like Dr. Roman, the mission remains clear: ensure that the best available technology is working for the patient, from the very first day of their evaluation.
About Dr. Tamara Roman
Dr. Tamara Roman, PhD, currently serves as a Variant Analyst at UNC Health. Her work focuses on the intersection of variant classification, genomic technology, and the clinical implementation of sequencing data to improve patient outcomes.
About the Author
